ResApp provides paediatric study results

Company News

by Carolyn Herbert

ResApp Health Limited (ASX:RAP) says it has delivered excellent results in its Australian pediatric SmartCough C study.

The study has enrolled more than 1,100 children, where their cough sounds were used to diagnose respiratory disease.

Analysis of the dataset confirmed a high level of agreement between ResAppDx and the clinical diagnosis of patients.

This is the first study where ResAppDx has been used to diagnose a full range of respiratory diseases.

Shares in ResApp are trading 1.54 per cent higher at $0.33.


Carolyn Herbert

Finance News Network
Carolyn joined FNN in August 2015 as the Head of News and also presented the Market at Midday and the Market Wrap. With more than five years of broadcast journalism experience, Carolyn has worked as a finance anchor on the Sky News Business channel and as an anchor and reporter for ABC News. She is also a qualified corporate lawyer specialising in IPOs, takeovers and mergers and acquisitions.